GlassScriptPhysician profile
Erin Haskin
NPI 1235747221
$2,117.67
in general payments reported to CMS, 2019-2025
32 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $446 · 2023: $361 · 2024: $476 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.34 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $280.75 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $153.45 | 2022-2025 | Farxiga, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $139.96 | 2022-2025 | Libtayo |
| Amgen INC. | $132.69 | 2021-2025 | Repatha, Otezla, Evenity |
| Leo Pharma INC. | $121.05 | 2023-2025 | Adbry, Anzupgo |
| Medtronic, INC. | $106.44 | 2021-2025 | Minimed 780g, Minimed 770g |
| Pfizer INC. | $71.93 | 2024-2025 | |
| Seqirus USA INC | $71.52 | 2022-2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.61 | 2024 | Spevigo, Ofev |
| Merck Sharp & Dohme LLC | $57.10 | 2021-2024 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $47.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.84 | 2022 | |
| Dexcom, INC. | $33.27 | 2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $33.18 | 2023-2024 | Rexulti |
| Sanofi Pasteur INC. | $28.55 | 2023 | |
| Jazz Pharmaceuticals INC. | $25.13 | 2025 | |
| Verona Pharma, INC. | $21.94 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.65 | 2024 | Xifaxan |
| Incyte Corporation | $21.11 | 2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $19.01 | 2025 | |
| Mallinckrodt Hospital Products INC. | $17.07 | 2022 | |
| Inogen, INC. | $16.21 | 2022 | |
| United Therapeutics Corporation | $15.60 | 2021 | |
| Fresenius Kabi USA, LLC | $15.17 | 2024 | Ivenix Infusion System |
| Allergan, INC. | $13.60 | 2021 | |
| Inari Medical, INC. | $13.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.09 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.97 | 2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $12.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Haskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.